STI-6129 is under clinical development by Sorrento Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STI-6129’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monoclonal antibody conjugate is under development for the treatment of multiple myeloma, relapsed or refractory systemic AL amyloidosis, T-cell acute lymphoblastic leukemia, lung cancer, head and neck squamous cell carcinoma, colorectal cancer and esophageal squamous cell carcinoma. The therapeutic candidate acts by targeting CD38. The therapeutic candidate comprises of human monoclonal anti-CD38 A2 antibody (STI-5171) covalently bound by a chemical linker to a dolastatin tubulin inhibitor chemotherapeutic derivative (duostatin 5.2). It is based on G-MAB and C-lock and K-lock conjugation technologies.
Sorrento Therapeutics overview
Sorrento Therapeutics (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is also investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.
For a complete picture of STI-6129’s drug-specific PTSR and LoA scores, buy the report here.